Techcyte

Deep learning classification of cells, parasites, bacteria, and cancer on digitized slides is the product, and the company frames the workflow platform as built around the algorithms rather than the reverse. The president's own description is unusually precise about the division of labour: the AI analyzes pixels and proposes high confidence targets, and the workflow adapts those proposals to how the lab already works.

Training data provenance is unusually specific: a long standing Mayo Clinic collaboration providing access to the Safe Harbour dataset of more than 17 million de-identified slides paired with pathology reports. Naming the institutional source and the scale lets a buyer reason about representativeness. Held back from A because no published accuracy, sensitivity, or specificity figures were retrieved for any classifier, which matters more given the Research Use Only status, since a laboratory cannot rely on regulatory review to have examined performance.

The single most important fact for a US buyer, and the company states it clearly rather than burying it: the anatomic and clinical pathology platform and the human products, covering parasitology, bacteriology, hematology, cervical cytology, and bladder cancer surveillance, are Research Use Only in the United States. Fusion carries CE-IVDD marking in Europe. Research Use Only is a permitted use restriction, not a stage of development: the product is real, sold, and generating revenue, but its outputs may not be used for clinical diagnostic purposes in the US. That also explains the segment economics, since veterinary diagnostics face no equivalent restriction and that segment is reported profitable while human is not. Graded on US clinical availability; the disclosure itself is a credit to the company.

One disclosed design choice deserves scrutiny. The company states that semi quantitative ranges for the peripheral blood smear classifier can be adjusted per customer to match their protocols and populations. Configurability is genuinely useful and honest to disclose, but it moves part of the clinical risk decision onto the laboratory: a threshold set for throughput behaves differently from one set for sensitivity, and no guidance, default rationale, or validation requirement for customer tuning was retrieved. Population adaptation is also raised as a rationale without any accompanying analysis of performance across populations.

Openness is an explicit commercial strategy rather than a feature. The platform connects to numerous slide scanners rather than requiring proprietary hardware, integrates with laboratory information systems, and hosts third party algorithms through the Fusion Partner Program. For a laboratory, not being locked to one scanner vendor is a substantive procurement advantage, and hosting external models means the platform can outlive any single algorithm. Buyers should note the corollary: models on the same screen may carry different regulatory status, as the Modella PathChat integration illustrates.

No public pricing. Contact the vendor. Sold to human, veterinary, and environmental laboratories, with the veterinary segment reported profitable and human and environmental targeted for 2027. US buyers should factor the Research Use Only restriction into any business case, since a product that cannot inform clinical diagnosis has a materially narrower internal use case than the same platform in Europe.